Q1 2025 Geron Corp Earnings Call Transcript
Key Points
- RYTELO's US commercial launch is the top corporate priority, with a focus on increasing brand awareness and expanding prescriber base.
- Geron Corp (GERN) has a strong financial position with approximately $457.5 million in cash and equivalents as of March 31, 2025.
- The company is implementing strategic enhancements to support US commercial success, including increasing the sales team by more than 20%.
- RYTELO has received positive feedback for its efficacy and manageable safety profile, particularly in hard-to-treat lower-risk MDS patients.
- Geron Corp (GERN) is pursuing a disciplined approach to EU commercialization, leveraging third-party partnerships to minimize investment.
- Q1 RYTELO net revenues were $39.4 million, down $8 million from Q4, attributed to inventory drawdown among distributors.
- Demand for RYTELO was relatively flat, with only a 1% increase in the 13-week period ending March 28 compared to the prior 13 weeks.
- The company is facing challenges in expanding RYTELO's use in earlier lines of treatment, with most usage currently in the third-line plus setting.
- There is hesitancy among some healthcare providers to switch patients from standard care to RYTELO, partly due to concerns about cytopenias.
- Geron Corp (GERN) is still in the process of identifying a permanent Chief Executive Officer, with a decision expected within the next six months.
Hello and welcome to the Geron's first-quarter 2025 early learning conference. (Operator Instructions)
I would now like to turn the conference over to Ron Moldaver, Investor Relations. You may begin.
Good morning, everyone. Welcome to the Geron Corporation's first-quarter 2025 earnings conference call. Before we begin, please note that during the course of this presentation and question-and-answer session, we will be making forward-looking statements regarding future events, performance, plans, expectations, and other projections, including those related to the launch, commercial opportunity, and therapeutic potential of RYTELO, anticipated clinical and commercial events and related timelines, the sufficiency of Geron's financial resources, and other statements that are not historical facts.
Actual events or results could differ materially. Therefore, I refer you to the discussion under the heading risk factors in Geron's most recent periodic report with the SEC, which identifies important factors that could
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
